Stock Quote
Neurobiological Technologies, Inc. (NTII.W) (NASD ADF)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View NTII on other exchanges
$0.22
19 Nov 2009
+34.38%
$0.91
$0.27
4,000
$0.27
$0.22
$1.05
$0.19
-0.34
110,138
NTII.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Fletcher, William | Acting Chief Executive Officer, Director | 196,941 |
| Loar, Matthew | Chief Financial Officer, Vice President, Director | 511,521 |
| Stuppin, John | Director | -- |
Profile
Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing investigational drugs for central nervous system conditions. In January 2009, the Company terminated development of its most advanced product candidate, Viprinex, which was studied in Phase 3 clinical trials as a... Full Description
Company Address
Neurobiological Technologies, Inc.
2000 Powell Street
Suite 800
Emeryville CA 94608
P: +1510.5956000
F: +1510.5956006
2000 Powell Street
Suite 800
Emeryville CA 94608
P: +1510.5956000
F: +1510.5956006
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Genentech, Inc. | -- | -- |
| Forest Laboratories, Inc. | $29.98 | +0.41 |
| Matrixx Initiatives, Inc. | $4.18 | -0.04 |
| NTII.W | Industry | |
|---|---|---|
| P/E(TTM) | 1.98 | 3.57 |
| P/S(TTM) | 0.23 | 0.57 |
| ROI(TTM) | 10.83 | 1.86 |
| ROE(TTM) | 14.41 | 2.51 |
| Consensus Recommendation | |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $16.28M |
| Net Income | $14.15M |
| EPS | $0.53 |
